Isotretinoin
Isotretinoin is a teratogen; there is about a 20–35% risk for congenital defects in infants exposed to the drug "in utero", and about 30–60% of children exposed to isotretinoin prenatally have been reported to show neurocognitive impairment. Because of this, there are strict controls on prescribing isotretinoin to women who may become pregnant and women who become pregnant while taking isotretinoin are strongly advised to terminate their pregnancies.
Ceftazidime/avibactam
Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose combination drug containing an antibiotic—3rd generation cephalosporin ceftazidime and a novel non-β-lactam β-lactamase inhibitor avibactam. It was approved for use in the United States in February 2015, and is sold under the brand name Avycaz, marketed by Allergan. In Europe, it was approved by the European Medicines Agency in 2016 and is sold as Zavicefta.